Acciones de Novartis AG (NVS) — ¿es un buen negocio?

Acciones de Novartis AG (NVS) — ¿es un buen negocio? — InspectStocks

Cómo gana dinero

Prescription medicines

Compite con

RHHBYRoche

Qué vende6

Entresto
A pill used to treat certain types of chronic heart failure, when the heart cannot pump or fill with blood properly.
Cosentyx
An injection for inflammatory conditions including psoriasis, some forms of arthritis and a chronic skin disease called hidradenitis suppurativa.
Kisqali
A cancer medicine used with hormone treatment for certain types of breast cancer.

Mostrar 3 más

Kesimpta
A monthly self-injection for adults with relapsing forms of multiple sclerosis, a disease in which the immune system damages nerves.
Pluvicto
An intravenous treatment that delivers radioactive particles to certain prostate cancer cells.
Leqvio
An injection given by a health professional to lower low-density lipoprotein (LDL) cholesterol, a type of fat in the blood.

Quién se lo compra5

Drug wholesalers buy medicines for resale to pharmacies and healthcare providers.
Retail and specialty pharmacies dispense medicines to patients, including drugs that need special handling.
Hospitals and private health systems buy medicines for treatment in their facilities.

Mostrar 2 más

Government agencies and government-supported health systems buy or fund medicines for patients.
Insurers and managed-care organizations influence which medicines are covered and reimbursed.

En qué se apoya y qué podría romperlo

De qué depende el negocio

1Sales of branded medicines depend on patent rights and regulatory exclusivity; generic or biosimilar competitors can enter after protections expire or are successfully challenged.
2Some medicines depend on licenses, collaborations or other agreements with outside drug developers.
3Manufacturing depends on specialized materials and tightly controlled production processes; some products may have limited alternative suppliers.
4Access to medicines depends on health-authority approval and on insurers or government health systems deciding whether and how much to reimburse.

Qué podría salir mal

1Generic competition and patent challenges can reduce sales when drug protections expire or competitors successfully challenge them; Novartis has also faced generic erosion for established medicines.
2Government price controls, Medicare price negotiations, required rebates and insurer coverage decisions can limit the prices Novartis receives or restrict patient access.
3Drug candidates can fail clinical trials or fail to receive approval after years of research and testing, leaving Novartis without a marketable medicine and with development costs already incurred.

Estados financieros completos →

Sobre Novartis AG

Novartis researches, tests, manufactures and sells prescription medicines in about 120 countries (2025, high). Its research focuses on heart, kidney and metabolic diseases, immune disorders, brain and nerve diseases, and cancer. Net sales were USD 54.532 billion (FY2025, high).

Sede: Basel, Switzerland
Fundada en: 1996
Empleados: 75,267 (December 31, 2025, high)
Cotiza en: NYSE
Cierre del ejercicio: December 31

Construido a partir de los propios informes de Novartis AG ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.

Keep exploring

The themes Novartis is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Highest-graded in Drug Manufacturers General

Graded A or B and worth $2B or more: A first, then the largest.

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

Cómo gana dinero

Prescription medicines

Compite con

RHHBYRoche

Qué vende6

Entresto
A pill used to treat certain types of chronic heart failure, when the heart cannot pump or fill with blood properly.
Cosentyx
An injection for inflammatory conditions including psoriasis, some forms of arthritis and a chronic skin disease called hidradenitis suppurativa.
Kisqali
A cancer medicine used with hormone treatment for certain types of breast cancer.

Mostrar 3 más

Kesimpta
A monthly self-injection for adults with relapsing forms of multiple sclerosis, a disease in which the immune system damages nerves.
Pluvicto
An intravenous treatment that delivers radioactive particles to certain prostate cancer cells.
Leqvio
An injection given by a health professional to lower low-density lipoprotein (LDL) cholesterol, a type of fat in the blood.

Quién se lo compra5

Drug wholesalers buy medicines for resale to pharmacies and healthcare providers.
Retail and specialty pharmacies dispense medicines to patients, including drugs that need special handling.
Hospitals and private health systems buy medicines for treatment in their facilities.

Mostrar 2 más

Government agencies and government-supported health systems buy or fund medicines for patients.
Insurers and managed-care organizations influence which medicines are covered and reimbursed.

En qué se apoya y qué podría romperlo

De qué depende el negocio

1Sales of branded medicines depend on patent rights and regulatory exclusivity; generic or biosimilar competitors can enter after protections expire or are successfully challenged.
2Some medicines depend on licenses, collaborations or other agreements with outside drug developers.
3Manufacturing depends on specialized materials and tightly controlled production processes; some products may have limited alternative suppliers.
4Access to medicines depends on health-authority approval and on insurers or government health systems deciding whether and how much to reimburse.

Qué podría salir mal

1Generic competition and patent challenges can reduce sales when drug protections expire or competitors successfully challenge them; Novartis has also faced generic erosion for established medicines.
2Government price controls, Medicare price negotiations, required rebates and insurer coverage decisions can limit the prices Novartis receives or restrict patient access.
3Drug candidates can fail clinical trials or fail to receive approval after years of research and testing, leaving Novartis without a marketable medicine and with development costs already incurred.

Estados financieros completos →

Sobre Novartis AG

Sede: Basel, Switzerland
Fundada en: 1996
Empleados: 75,267 (December 31, 2025, high)
Cotiza en: NYSE
Cierre del ejercicio: December 31

Cómo gana dinero

Compite con

Qué vende6

Quién se lo compra5

En qué se apoya y qué podría romperlo

De qué depende el negocio

Qué podría salir mal

Sobre Novartis AG

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Cómo gana dinero

Compite con

Qué vende6

Quién se lo compra5

En qué se apoya y qué podría romperlo

De qué depende el negocio

Qué podría salir mal

Sobre Novartis AG

Novartis AG

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Big pharma

Crecimiento y caja — 5 de 5

Precio de la acción y calificación a lo largo del tiempo

Cómo gana dinero

Compite con

Qué vende6

Quién se lo compra5

En qué se apoya y qué podría romperlo

De qué depende el negocio

Qué podría salir mal

Sobre Novartis AG

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Cómo gana dinero

Compite con

Qué vende6

Quién se lo compra5

En qué se apoya y qué podría romperlo

De qué depende el negocio

Qué podría salir mal

Sobre Novartis AG

Novartis AG

Rentabilidad pasada

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Big pharma

Crecimiento y caja — 5 de 5

Precio de la acción y calificación a lo largo del tiempo